Potential Antiangiogenic Treatment Eligibility of Patients with Squamous Non-Small-Cell Lung Cancer: EPISQUAMAB Study (GFPC 2015-01).

Alain VergnenegreVictor BasseGwenaelle Le GarffOlivier BylickiCatherine Dubos-ArvisBénédicte CometMarie MarcqJacques Le TreutJean-Bernard AuliacAnne MadroszykGislaine Fraboulet Jacky CrequitPascal ThomasNicolas PaleironIsabelle Monnetnull null

Published in: Cancer management and research (2019)

Almost half of the SQ-NSCLC patients included in this study would have been eligible to receive an antiVEGF agent. The development of these molecules for these indications should be encouraged.

Keyphrases

end stage renal disease
small cell lung cancer
chronic kidney disease
ejection fraction
high grade
low grade
replacement therapy